Semaphorin-7A on Exosomes: A Promigratory Signal in the Glioma Microenvironment.
Semaphorin 7A
exosomes
glioblastoma microenvironment
integrin β1/FAK signalling
motility
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 May 2019
30 May 2019
Historique:
received:
09
05
2019
revised:
24
05
2019
accepted:
25
05
2019
entrez:
2
6
2019
pubmed:
4
6
2019
medline:
4
6
2019
Statut:
epublish
Résumé
Exosomes are one of the most important mediators of the cross talk occurring between glioma stem cells (GSCs) and the surrounding microenvironment. We have previously shown that exosomes released by patient-derived glioma-associated stem cells (GASC) are able to increase, in vitro, the aggressiveness of both GSC and glioblastoma cell lines. To understand which molecules are responsible for this tumour-supporting function, we performed a descriptive proteomic analysis of GASC-exosomes and identified, among the others, Semaphorin7A (SEMA7A). SEMA7A was described as a promigratory cue in physiological and pathological conditions, and we hypothesised that it could modulate GSC migratory properties. Here, we described that SEMA7A is exposed on GASC-exosomes' surface and signals to GSC through Integrin β1. This interaction activates focal adhesion kinase into GSC and increases their motility, in our patient-based in vitro model. Our findings suggest SEMA7A-β1-integrin as a new target to disrupt the communication between GSCs and the supporting microenvironment.
Identifiants
pubmed: 31151295
pii: cancers11060758
doi: 10.3390/cancers11060758
pmc: PMC6628148
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Interreg Italia-Austria 2014-2020: "EXOTHERA - Exosomes for regenerative, immunosuppressive, neuroprotective, and oncosuppressive therapies
ID : G22F16000900006
Organisme : "Glioblastoma - Infiltrazione nei gliomi: nuovo target terapeutico"
ID : G23C17000600007
Organisme : BioMec - Applicazione delle tecnologie biomeccaniche a integrazione delle metodiche tradizionali nel contesto ospedaliero
ID : G22F16000960007
Organisme : TRANS-GLIOMA - Nuove terapie per il glioblastoma tramite una piattaforma di ricerca transfrontaliera traslazionale
ID : J22F17000100005
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Références
Cell. 1999 Oct 1;99(1):71-80
pubmed: 10520995
Eur Radiol. 2001;11(1):131-6
pubmed: 11194904
Mech Dev. 2001 Apr;102(1-2):145-56
pubmed: 11287188
Biochim Biophys Acta. 2001 Jul 25;1540(1):1-21
pubmed: 11476890
Scand J Immunol. 2002 Sep;56(3):270-5
pubmed: 12193228
J Cell Sci. 2003 Apr 15;116(Pt 8):1409-16
pubmed: 12640026
Nature. 2003 Jul 24;424(6947):398-405
pubmed: 12879062
EMBO Rep. 2004 Apr;5(4):356-61
pubmed: 15060572
Curr Opin Genet Dev. 2004 Feb;14(1):92-101
pubmed: 15108811
Int Immunol. 2005 Apr;17(4):439-47
pubmed: 15746246
Cancer Res. 2006 Aug 15;66(16):7843-8
pubmed: 16912155
Cancer Cell. 2007 Jan;11(1):69-82
pubmed: 17222791
Nature. 2007 Apr 5;446(7136):680-4
pubmed: 17377534
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
J Invest Dermatol. 2008 Jan;128(1):151-61
pubmed: 17671519
Int Rev Cytol. 2007;263:103-53
pubmed: 17725966
BMC Dev Biol. 2007 Aug 29;7:98
pubmed: 17727705
Trends Biochem Sci. 2008 Apr;33(4):161-70
pubmed: 18374575
J Biol Chem. 2008 Nov 21;283(47):32264-72
pubmed: 18806266
Proteomics. 2008 Nov;8(22):4721-32
pubmed: 18850631
J Invest Dermatol. 2009 Apr;129(4):954-63
pubmed: 18987670
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Cell Stem Cell. 2011 May 6;8(5):482-5
pubmed: 21549324
J Proteome Res. 2011 Jul 1;10(7):3149-59
pubmed: 21574646
Arch Neurol. 2012 Apr;69(4):523-6
pubmed: 22158715
Genes Dev. 2012 Jun 15;26(12):1287-99
pubmed: 22713869
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
Nat Rev Neurosci. 2012 Sep;13(9):605-18
pubmed: 22895477
Cell. 2012 Dec 21;151(7):1542-56
pubmed: 23260141
Semin Cell Dev Biol. 2013 Mar;24(3):129-38
pubmed: 23333497
Mol Cancer. 2013 Mar 25;12:22
pubmed: 23522389
Cell. 2013 Mar 28;153(1):139-52
pubmed: 23540695
J Biol Chem. 2013 Sep 27;288(39):28398-408
pubmed: 23926108
PLoS One. 2013 Oct 24;8(10):e78631
pubmed: 24302979
Cancer Res. 2014 Feb 1;74(3):738-750
pubmed: 24310399
Stem Cells. 2014 May;32(5):1239-53
pubmed: 24375787
Br J Cancer. 2014 Mar 4;110(5):1199-210
pubmed: 24473397
PLoS One. 2014 Nov 12;9(11):e112582
pubmed: 25390644
Nat Commun. 2015 Feb 27;6:6385
pubmed: 25721933
Oncotarget. 2015 Mar 30;6(9):6670-83
pubmed: 25749384
Curr Opin Cell Biol. 2015 Aug;35:69-77
pubmed: 26001269
Biochim Biophys Acta. 2016 Mar;1863(3):427-437
pubmed: 26264495
Hum Mol Genet. 2015 Dec 1;24(23):6624-39
pubmed: 26362255
Oncogene. 2016 May 19;35(20):2615-23
pubmed: 26364614
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Cell Mol Neurobiol. 2016 Apr;36(3):301-12
pubmed: 27053351
Oncogene. 2016 Sep 29;35(39):5170-8
pubmed: 27065336
Biomed Rep. 2016 Aug;5(2):203-207
pubmed: 27446542
J Biomed Res. 2016 May;30(3):217-24
pubmed: 27533932
Acta Biochim Biophys Sin (Shanghai). 2017 Jan;49(1):62-73
pubmed: 27864281
Nat Commun. 2017 Mar 10;8:14666
pubmed: 28281529
Cancers (Basel). 2017 Aug 23;9(9):null
pubmed: 28832494
Cell Stem Cell. 2018 Apr 5;22(4):514-528.e5
pubmed: 29625067
Biomed Pharmacother. 2018 Sep;105:83-94
pubmed: 29852393
Bioessays. 1995 Mar;17(3):229-36
pubmed: 7748177
Cell. 1993 Dec 31;75(7):1389-99
pubmed: 8269517
Lab Invest. 1996 Dec;75(6):819-26
pubmed: 8973477